Determination of Blood Loss After CS

Ain Shams University

Status and phase: Unknown; Early Phase 1

Conditions: Effect of Drug

Treatments: Drug: Tranexamic acid; Drug: Oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT04549012

blood loss after CS

Details and patient eligibility

About

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

Full description

tranexamic acid plus oxytocin versus oxytocin only in reducing blood loss following CS

Enrollment: 130 estimated patients

Sex: Female

Ages: 20 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age : 20-40 year

   • 2- Gestational age is between 37-41weeks

3- Delivery by uncomplicated elective CS

Exclusion criteria

• 1- Risk factors for uterine atony such as polyhydramnios or fetal macrosomia. 2- Grandmultiparity 3- Past history of postpartum hemorrhage either atonic or traumatic 4- Previous history of retained placenta 5- Pre-eclampsia or gestational hypertension/ Maternal DM 6- Abnormal placentation 7- Contraindications to the use of tranexamic acid 8- Hypersensitivity to tranexamic acid. 9- Women receiving anticoagulant therapy. 10- having underlying disease (heart, liver, kidney, pulmonary, etc.),

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

130 participants in 2 patient groups

group A

Active Comparator group

Description:

will receive oxytocin

Treatment:

Drug: Oxytocin

group B

Active Comparator group

Description:

will receive tranexamic acid plus oxytocin

Treatment:

Drug: Tranexamic acid